GlycoNex Incorporation (TPEX:4168)

Market Cap	2.75B
Revenue (ttm)	19.03M
Net Income (ttm)	-201.48M
Shares Out	108.21M
EPS (ttm)	-1.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	526,495
Average Volume	1,051,763
Open	25.70
Previous Close	25.65
Day's Range	25.25 - 26.75
52-Week Range	15.60 - 31.85
Beta	0.52
RSI	51.59
Earnings Date	Aug 12, 2025

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the develop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4168

Financial Performance

In 2024, GlycoNex Incorporation's revenue was 14.70 million, an increase of 478.32% compared to the previous year's 2.54 million. Losses were -229.71 million, 28.8% more than in 2023.